What is the appropriate starting dose of atomoxetine (Strattera) for a 12‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Starting Dose of Strattera for a 12-Year-Old

Begin atomoxetine at 0.5 mg/kg/day for approximately 7 days, then increase to a target dose of 1.2 mg/kg/day, which can be administered either once daily in the morning or split into two divided doses (morning and late afternoon/early evening).

Dosing Algorithm

The FDA-approved dosing strategy for children and adolescents weighing ≤70 kg follows this specific titration schedule 1:

  • Initial dose: 0.5 mg/kg/day for minimum 7 days
  • Target dose: 1.2 mg/kg/day after the initial week
  • Maximum dose: 1.4 mg/kg/day or 100 mg/day (whichever is less)

For a typical 12-year-old weighing approximately 40 kg, this translates to:

  • Start: 20 mg/day for 7 days
  • Target: 48 mg/day thereafter
  • Maximum: 56 mg/day if needed

Dosing Flexibility

Atomoxetine can be given once daily in the morning OR split into two divided doses (early morning and late afternoon/early evening) 1, 2. Clinical trials demonstrate equivalent efficacy with both regimens, so choose based on the child's schedule and tolerability profile.

Evidence Supporting 1.2 mg/kg/day as Optimal Target

Multiple dose-response studies consistently demonstrate that 1.2 mg/kg/day provides maximal symptom improvement without additional benefit at higher doses 2. In the pivotal dose-response trial, atomoxetine at 1.2 mg/kg/day and 1.8 mg/kg/day showed equivalent efficacy, both superior to 0.5 mg/kg/day and placebo, establishing 1.2 mg/kg/day as the appropriate initial target 2. A Korean pediatric study confirmed this graded dose-response, showing mean ADHD Rating Scale improvements of -9.6, -12.3, and -14.5 points at 0.2,0.5, and 1.2 mg/kg/day respectively 3.

Critical Titration Considerations

Avoid rapid dose escalation to minimize gastrointestinal side effects and initial somnolence 4. The FDA label specifically warns that increasing dosage too rapidly increases the risk of these adverse effects 1. The 7-day minimum at 0.5 mg/kg/day allows for tolerability assessment before reaching the therapeutic target.

If the child experiences significant gastrointestinal symptoms (nausea, vomiting, decreased appetite) or somnolence during titration, maintain the current dose for an additional week before advancing.

Monitoring Requirements

Before initiating atomoxetine:

  • Obtain personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome) 4
  • Measure baseline heart rate and blood pressure
  • If cardiac risk factors present, obtain ECG and consider cardiology consultation 4

During treatment:

  • Monitor heart rate and blood pressure at each dose adjustment
  • Assess for suicidal ideation (FDA black box warning) 4
  • Monitor growth parameters (height/weight) as atomoxetine may cause temporary growth delays in the first 1-2 years 4
  • Watch for rare hepatotoxicity signs (jaundice, dark urine, right upper quadrant tenderness)

Timeline for Response

Expect progressive symptom improvement over 6-12 weeks 5. Unlike stimulants, atomoxetine requires sustained treatment to achieve maximal benefit. In treatment-naïve patients, between-group differences versus placebo increased progressively from week 6 to week 12, with 50% of patients achieving ≥40% symptom reduction by week 12 5.

Common Pitfalls to Avoid

  1. Stopping too early: Many families expect immediate stimulant-like effects. Counsel that full response requires 6-12 weeks of consistent dosing.

  2. Inadequate dose: Stopping at 0.5 mg/kg/day provides suboptimal efficacy. The evidence clearly supports advancing to 1.2 mg/kg/day unless tolerability issues prevent it 2.

  3. Abrupt discontinuation: While not as critical as with alpha-2 agonists, gradual taper is preferable if discontinuing.

  4. Missing cardiac screening: The cardiovascular history is mandatory before starting, particularly given atomoxetine's effects on heart rate and blood pressure 4.

Special Circumstances

If the child is a known CYP2D6 poor metabolizer (approximately 7% of Caucasians), atomoxetine exposure increases 10-fold. In these patients, start at 0.5 mg/kg/day and titrate more slowly, with a lower target dose of 0.5-0.8 mg/kg/day 1, 6.

For patients with moderate hepatic impairment, reduce all doses by 50%; for severe hepatic impairment, reduce by 75% 1.

References

Related Questions

What is the appropriate starting dose of Strattera (atomoxetine) for children, adolescents, and adults?
What is a safe starting dose of atomoxetine (Strattera) for a 14‑year‑old male with ADHD and depression, weighing 50 kg, who cannot tolerate stimulant medications?
For a 7‑year‑old child, what initial dose of Strattera (atomoxetine) should be used and which side effects need to be monitored?
What is the appropriate starting dose of atomoxetine (Strattera) for an 11-year-old child with ADHD who weighs 100 lb (approximately 45 kg)?
What is the recommended way to increase a child's atomoxetine (Strattera) dose from 18 mg to 25 mg?
Does ezetimibe increase the risk of cholangitis?
When should a urine culture be obtained, how should the specimen be collected, and what colony count defines a positive result?
What is the most common adverse effect of phosphodiesterase‑5 inhibitors such as Revatio (sildenafil) for pulmonary arterial hypertension and Viagra (sildenafil) for erectile dysfunction?
Can dapagliflozin be used in patients with end‑stage renal disease (ESRD)?
For a woman with a prior history of endometrial hyperplasia, what oral progestin regimen is recommended?
How should I initiate warfarin (generic) therapy when only 2.5 mg tablets are available?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.